These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 34321067)
1. Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy. Freigang M; Steinacker P; Wurster CD; Schreiber-Katz O; Osmanovic A; Petri S; Koch JC; Rostásy K; Falkenburger B; Ludolph AC; Otto M; Hermann A; Günther R Orphanet J Rare Dis; 2021 Jul; 16(1):330. PubMed ID: 34321067 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy. Kobayashi Y; Ishikawa N; Tateishi Y; Izumo H; Eto S; Eguchi Y; Okada S Brain Dev; 2023 Jan; 45(1):2-7. PubMed ID: 36210235 [TBL] [Abstract][Full Text] [Related]
3. Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months. De Wel B; De Schaepdryver M; Poesen K; Claeys KG Ann Clin Transl Neurol; 2022 Aug; 9(8):1241-1251. PubMed ID: 35833245 [TBL] [Abstract][Full Text] [Related]
4. Nusinersen: A Review in 5q Spinal Muscular Atrophy. Hoy SM CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360 [TBL] [Abstract][Full Text] [Related]
5. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M; J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549 [TBL] [Abstract][Full Text] [Related]
6. Treatment of Symptomatic Spinal Muscular Atrophy with Nusinersen: A Prospective Longitudinal Study on Scoliosis Progression. Ip HNH; Yu MKL; Wong WHS; Liu A; Kwan KYH; Chan SHS J Neuromuscul Dis; 2024; 11(2):349-359. PubMed ID: 38363614 [TBL] [Abstract][Full Text] [Related]
7. Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis. Fox D; To TM; Seetasith A; Patel AM; Iannaccone ST Adv Ther; 2023 Mar; 40(3):903-919. PubMed ID: 36534265 [TBL] [Abstract][Full Text] [Related]
8. Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen. Garofalo M; Bonanno S; Marcuzzo S; Pandini C; Scarian E; Dragoni F; Di Gerlando R; Bordoni M; Parravicini S; Gellera C; Masson R; Dosi C; Zanin R; Pansarasa O; Cereda C; Berardinelli A; Gagliardi S Biol Direct; 2023 Sep; 18(1):57. PubMed ID: 37705059 [TBL] [Abstract][Full Text] [Related]
9. Nusinersen for the treatment of spinal muscular atrophy. Chiriboga CA Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620 [TBL] [Abstract][Full Text] [Related]
10. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. Meyer T; Maier A; Uzelac Z; Hagenacker T; Günther R; Schreiber-Katz O; Weiler M; Steinbach R; Weyen U; Koch JC; Kettemann D; Norden J; Dorst J; Wurster C; Ludolph AC; Stolte B; Freigang M; Osmanovic A; Petri S; Grosskreutz J; Rödiger A; Griep R; Gaudlitz M; Walter B; Münch C; Spittel S Eur J Neurol; 2021 Aug; 28(8):2582-2595. PubMed ID: 33960080 [TBL] [Abstract][Full Text] [Related]
11. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study. Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience. Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971 [TBL] [Abstract][Full Text] [Related]
13. Children and young adults with spinal muscular atrophy treated with nusinersen. Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321 [TBL] [Abstract][Full Text] [Related]
14. Nusinersen: A Review in 5q Spinal Muscular Atrophy. Hoy SM CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400 [TBL] [Abstract][Full Text] [Related]
15. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy. Osmanovic A; Ranxha G; Kumpe M; Müschen L; Binz C; Wiehler F; Paracka L; Körner S; Kollewe K; Petri S; Schreiber-Katz O J Neurol; 2020 Aug; 267(8):2398-2407. PubMed ID: 32361837 [TBL] [Abstract][Full Text] [Related]